Biosimilars: A Tipping Point

December 14, 2016

With biosimilars, the U.S. healthcare industry has a remarkable opportunity to make lifesaving and disease-altering drugs more accessible and more affordable. Read more.

Previous Article
Rethink: Healthcare in 2017
Rethink: Healthcare in 2017

Here are three focus areas for the Trump Administration that will help capitalize on the healthcare gains w...

Next Video
What Are Biosimilars?
What Are Biosimilars?

Watch to learn more.